Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHL TelemedicineSHMLF 52 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates SHMLF with a GF Score™ of 52/100 and a GF Value™ of $12.09. The stock has 3 warning signs investors should review. Among 524 Healthcare Providers & Services companies, SHL Telemedicine ranks worse than 190839.5% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of SHL Telemedicine was 210.90% per year. The lowest was -134.00% per year. And the median was -17.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
SHL Telemedicine 3-Year EBITDA Growth Rate Related Terms
SHMLF vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, SHL Telemedicine's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
SHL Telemedicine (SHMLF) has a 3-Year EBITDA Growth Rate of 0.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SHL Telemedicine and its competitors. According to the industry distribution chart, SHL Telemedicine ranks #999999 out of 524 companies in the Healthcare Providers & Services industry.
Is SHL Telemedicine's 3-Year EBITDA Growth Rate too high?
SHL Telemedicine's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, SHL Telemedicine ranks #999999 out of 524 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, SHL Telemedicine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #999999 out of 524 companies for 3-Year EBITDA Growth Rate. This places SHL Telemedicine in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.25, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SHL Telemedicine and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current 3-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is $12.09, compared to a current price of $4.84 — trading 59.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. SHL Telemedicine's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 59.9% below its estimated GF Value™ of $12.09.
Key valuation signals for SHMLF:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $12.09 vs. price of $4.84 (59.9% below fair value)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
52GF Score
Get the complete analysis for SHMLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
